<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682367</url>
  </required_header>
  <id_info>
    <org_study_id>1166778</org_study_id>
    <nct_id>NCT03682367</nct_id>
  </id_info>
  <brief_title>Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery</brief_title>
  <official_title>Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing head and neck cancer surgery often have a lot of pain after surgery,
      which can lead to a need for a lot of narcotic pain medication. These medications can have
      many side effects that can make recovery more difficult including nausea, vomiting,
      dizziness, being overly sleepy, itchiness, inability to urinate, confusion, inability to have
      a bowel movement, longer time before being able to start walking. These side effects can make
      the hospital stay longer. The use of gabapentin, which is a non narcotic pain medication that
      focuses on nerve pain, has been used in smaller head and neck surgeries including removal of
      tonsils, sinus surgery, thyroid surgery. Studies in patients needing orthopedic or OB/Gyn
      surgery have shown improved pain control with gabapentin. Potential benefits to future
      patients include improved pain control, less narcotic associated side effects and faster
      functional recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing head and neck cancer surgery frequently experience significant post
      surgical pain, which often necessitates the use of narcotic pain medication. However, opioids
      can have multiple side effects that can complicate the head and neck cancer surgery patients
      postoperative care including nausea, vomiting, dizziness, sedation, pruritis, urinary
      retention, delirium, constipation, and time to ambulation. This, in turn, may affect patient
      length and cost of hospital stay. Consequently, a multimodal approach to analgesia is often
      employed with a focus on use of scheduled acetaminophen +/- NSAIDs supplemented with
      narcotics.

      The use of gabapentin in the head and neck surgery literature has largely been limited to
      outpatient surgeries, including tonsillectomy in children and adults, functional endoscopic
      sinus surgery, and thyroidectomy. Indeed, a recent systematic review examined RCT comparing
      multimodal analgesia with gabapentin to analgesia without gabapentin in the otolaryngology
      literature. The majority of these studies employed preoperative dosing only, with only 1
      study providing a single postoperative dose as well. The control group pain regimen among
      these studies did vary and included a combination of acetaminophen, NSAIDs, dexmedetomidine,
      or clonidine supplemented with opioids. The studies focused on the impact of gabapentin on
      acute postoperative pain determined by subjective measurement of reduction in visual analog
      pain scale. Of note, these patients were not hospitalized for longer than 24 hours. The
      thyroid and sinus studies consistently demonstrated improved pain control with use of
      gabapentin compared to control. The data was slightly more variable across the tonsillectomy
      studies. Moreover, 7 studies also measured the need for breakthrough pain medication and
      supplemental analgesia; each of these studies demonstrated significantly less supplemental
      analgesia consumption in the gabapentin group.

      The only study examining the utility of gabapentin in pain management in head and neck cancer
      patients (glossectomy with anterolateral thigh free flap) examined the utility of a single
      preoperative dose. The authors concluded that this led to a significant reduction in
      subjective postoperative pain scores, morphine requirement, and nausea and vomiting compared
      to controls. This study did not employ postoperative gabapentin.

      Furthermore, a recent meta analysis (133 RCT) examining literature across multiple surgical
      specialties pertaining to the efficacy of perioperative gabapentin supplementation vs
      placebo. The meta analysis indicated both the efficacy of gabapentin supplementation in
      decreasing opioid requirement (measured via morphine equivalent units) in the experimental
      group during the first 24 hours (P&lt;0.001), as well as a good safety profile across a wide
      range of loading and maintenance doses (200 to 1200 mg) of gabapentin. The significant
      reduction in opioid requirement was independent of surgery type. Moreover, the gabapentin
      group demonstrated a significant decrease in VAS postoperative pain scores, nausea, vomiting
      and itching; however, sedation scores were increased. Only 8 of these 133 RCT examined the
      effect of gabapentin outside the immediate 24 hour period, and all 8 trials demonstrated
      improvement in chronic pain scores at 3 months post-operatively. Finally, patient
      satisfaction scores and preoperative anxiety were also significantly improved with the use of
      gabapentin compared to controls.

      Here, the investigators propose, for the first time, a superiority double blind randomized
      controlled placebo trial examining the effect of perioperative supplementation with
      gabapentin in head and neck cancer patients undergoing surgery. The primary purpose of this
      study is to determine the difference in morphine equivalent units between the experimental
      (i.e. perioperative gabapentin) and control group (i.e. no perioperative gabapentin). The
      secondary purpose of this study is to determine differences across the two groups in relation
      to the following: visual analog pain scores, cost and length of stay, medication side
      effects, and incidence of postoperative complications. Of note, in order to maximize
      reliability of the visual analog scale (VAS), prior studies have employed the Jadad scoring
      system, which the investigators will also implement in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>All staff involved including nursing, surgeons, pain management, participants and PI will be blinded. Unmasked personnel only include research pharmacy staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Average Morphine Equivalent Units</measure>
    <time_frame>Perioperative.</time_frame>
    <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Morphine Equivalent Units</measure>
    <time_frame>1 week post-operation.</time_frame>
    <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Morphine Equivalent Units</measure>
    <time_frame>30 days post-operation.</time_frame>
    <description>Determine the difference in average morphine equivalent units between experimental and control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score (10 point VAS)</measure>
    <time_frame>Perioperative, 1 week post-operation, 1 week post-discharge, and 30 days post-operation.</time_frame>
    <description>Determine average change of inpatient Pain Score Visual Analog Scale (VAS) on a standardized 1 (no pain) to 10 (highest level of pain) scale between experimental and control groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Complications</measure>
    <time_frame>30 days post-operation.</time_frame>
    <description>Incidence of postoperative complications between experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotics-related Complications</measure>
    <time_frame>30 days post-operation.</time_frame>
    <description>Incidence of narcotics-related complications between experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Length of Stay</measure>
    <time_frame>1 week post-operation.</time_frame>
    <description>Determine the difference of average inpatient length of stay between experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Cost</measure>
    <time_frame>1 week post-operation.</time_frame>
    <description>Determine the difference of average inpatient cost between experimental and control group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <condition>Narcotic Use</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Use of Gabapentin peri- and post-operatively.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Neurontin</other_name>
    <other_name>Gralise</other_name>
    <other_name>Horizant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Concentrate</intervention_name>
    <description>Use of sugar-free Placebo peri- and post-operatively.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing major head and neck surgery with concomitant free flap
             reconstruction surgery at UCDMC (oncology and non-oncologic): There will be two
             groups. Group 1 will include reconstruction with fibula free flap only. Group 2 will
             include any other free flap reconstruction, including scapular free flap, radial
             forearm free flap, anterolateral thigh free flap, anteromedial thigh free flap, and
             latissimus dorsi free flap.

          -  Patients na√Øve to gabapentin

          -  Adult patients &gt;18 years of age and able to consent

        Exclusion Criteria:

          -  Patients who are already taking scheduled gabapentin

          -  Patients allergic to gabapentin

          -  Chronic opioid use not from active head and neck cancer

          -  Illicit drug use (per report)

          -  Patients with known renal compromise, such that Creatinine clearance is &lt; 30

          -  Patient with known hepatic insufficiency or cirrhosis

          -  Adults unable to consent

          -  Individuals less than 18 years old

          -  Pregnant women

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Bewley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Beliveau, MPH, CCRP</last_name>
    <phone>916-734-2704</phone>
    <email>ambeliveau@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Kim</last_name>
      <phone>916-734-2704</phone>
      <email>hmykim@ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>Narcotic</keyword>
  <keyword>Cancer</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

